WO2009039743A8 - Arnsi utiles pour l'inhibition de gene tyrosinase, compositions comportant les arnsi et leurs utilisations - Google Patents

Arnsi utiles pour l'inhibition de gene tyrosinase, compositions comportant les arnsi et leurs utilisations Download PDF

Info

Publication number
WO2009039743A8
WO2009039743A8 PCT/CN2008/072142 CN2008072142W WO2009039743A8 WO 2009039743 A8 WO2009039743 A8 WO 2009039743A8 CN 2008072142 W CN2008072142 W CN 2008072142W WO 2009039743 A8 WO2009039743 A8 WO 2009039743A8
Authority
WO
WIPO (PCT)
Prior art keywords
tyro
sirnas
tyrosinase gene
compositions
useful
Prior art date
Application number
PCT/CN2008/072142
Other languages
English (en)
Chinese (zh)
Other versions
WO2009039743A1 (fr
Inventor
梁子才
张鸿雁
Original Assignee
苏州瑞博生物技术有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 苏州瑞博生物技术有限公司 filed Critical 苏州瑞博生物技术有限公司
Priority to CN2008801029315A priority Critical patent/CN101820921B/zh
Publication of WO2009039743A1 publication Critical patent/WO2009039743A1/fr
Publication of WO2009039743A8 publication Critical patent/WO2009039743A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/18—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with another compound as one donor, and incorporation of one atom of oxygen (1.14.18)
    • C12Y114/18001—Tyrosinase (1.14.18.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Birds (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des ARNsi utiles pour inhiber l'expression du gène tyrosinase, les ARNsi ayant la séquence nucléotidique représentée dans TYRO-1, TYRO-2, TYRO-3, TYRO-4, TYRO-5, TYRO-6, TYRO-7 ou TYRO-8, ou la séquence nucléotidique chimiquement modifiée dérivée de la séquence nucléotidique représentée dans TYRO-1, TYRO-2, TYRO-3, TYRO-4, TYRO-5, TYRO-6, TYRO-7 ou TYRO-8. L'invention concerne également des compositions cosmétiques et les utilisations des ARNsi dans la préparation d'une composition cosmétique permettant d'inhiber la production et le dépôt de mélanine ou d'éliminer la mélanine. Les ARNsi présentent une activité élevée pour l''inhibition de l'expression du gène tyrosinase, et peuvent efficacement inhiber la production et le dépôt de mélanine.
PCT/CN2008/072142 2007-09-20 2008-08-26 Arnsi utiles pour l'inhibition de gene tyrosinase, compositions comportant les arnsi et leurs utilisations WO2009039743A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2008801029315A CN101820921B (zh) 2007-09-20 2008-08-26 一种抑制酪氨酸酶基因表达的siRNA及组合物和应用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200710153058 2007-09-20
CN200710153058.X 2007-09-20

Publications (2)

Publication Number Publication Date
WO2009039743A1 WO2009039743A1 (fr) 2009-04-02
WO2009039743A8 true WO2009039743A8 (fr) 2010-04-01

Family

ID=40510753

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2008/072142 WO2009039743A1 (fr) 2007-09-20 2008-08-26 Arnsi utiles pour l'inhibition de gene tyrosinase, compositions comportant les arnsi et leurs utilisations

Country Status (2)

Country Link
CN (1) CN101820921B (fr)
WO (1) WO2009039743A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102793639A (zh) * 2011-12-16 2012-11-28 百奥迈科生物技术有限公司 一种植物提取物介导的药物透皮导入系统及其透皮方法
CA3022872C (fr) * 2015-07-27 2024-01-09 Olix Pharmaceuticals, Inc. Complexes d'arn qui inhibent la production de melanine
KR20180025701A (ko) * 2016-09-01 2018-03-09 (주)아모레퍼시픽 특정 siRNA을 포함하는 멜라닌 증진용 조성물
CN110643596A (zh) * 2018-06-26 2020-01-03 煌鼎科技有限公司 一种美白酵母dna原料的制法
CN110066800B (zh) * 2019-04-30 2019-12-24 厦门甘宝利生物医药有限公司 一种化合物及其组合物的应用
CN113667669B (zh) * 2021-08-06 2023-12-22 暨南大学 抑制酪氨酸酶表达的反义寡核苷酸及其应用
CN117070583B (zh) * 2023-10-16 2024-05-14 吉林凯莱英制药有限公司 抑制PCSK9基因表达的siRNA的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1506041A (zh) * 2002-12-12 2004-06-23 殷冬生 基因皮肤美白化妆品的配方和制造方法
US7504385B2 (en) * 2003-12-17 2009-03-17 Avon Products, Inc. si-RNA-mediated gene silencing technology to inhibit tyrosinase and reduce pigmentation
FR2890859B1 (fr) * 2005-09-21 2012-12-21 Oreal Oligonucleotide d'arn double brin inhibant l'expression de la tyrosinase
CN101601635A (zh) * 2008-06-13 2009-12-16 殷勤伟 小rna/dna美白产品的配方和制造方法

Also Published As

Publication number Publication date
CN101820921B (zh) 2012-07-25
CN101820921A (zh) 2010-09-01
WO2009039743A1 (fr) 2009-04-02

Similar Documents

Publication Publication Date Title
WO2009039743A8 (fr) Arnsi utiles pour l'inhibition de gene tyrosinase, compositions comportant les arnsi et leurs utilisations
WO2007064857A3 (fr) Formulation de liposomes amphoteres
WO2008152131A3 (fr) Inhibition par arni de l'expression du canal alpha-enac
WO2011008730A3 (fr) Modification chimique de petits arn en épingle à cheveux pour l'inhibition d'une expression de gène
WO2009043353A3 (fr) Oligonucléotides micromir
EP4269584A3 (fr) Composés antisens sélectifs et leurs utilisations
WO2012018881A3 (fr) Procédés et compositions pour la régulation d'arn
WO2008085221A3 (fr) Utilisation thérapeutique de cellules exprimant cd31
EP2313491A4 (fr) Procédés, compositions et systèmes pour une bioproduction biosynthétique de 1,4-butanediol
WO2012058494A3 (fr) Variantes d'isoprène synthase pour l'augmentation de la production d'isoprène
WO2005118824A3 (fr) Methodes et compositions inhibant l'expression genique
WO2007027894A3 (fr) Composes antisens ayant une activite anti-microarn amelioree
SG165394A1 (en) Modulation of immunostimulatory properties of short interfering ribonucleic acid (sirna) by nucleotide modification
WO2007090073A3 (fr) Composes oligomeres et compositions utilises pour moduler les micro-arn
WO2009129465A3 (fr) Compositions et méthodes d'inhibition de l'expression du gène xbp-1
WO2009006297A3 (fr) Procédés de modification du génome d'une cellule de plante monocotylédone
WO2012024573A3 (fr) Compositions comprenant des cellules souches périvasculaires et la protéine nell-1
WO2010135836A8 (fr) Nouvelles enzymes bêta-glucosidases
WO2009108217A3 (fr) Compositions comprenant un arnsi de k-ras et procédés d’utilisation
WO2011116152A3 (fr) Administration d'agents par le biais de l'utilisation de nanoparticules interférentes
WO2007144779A3 (fr) Compositions comprenant des porphyra et procédés d'utilisation de celles-ci
WO2012054664A3 (fr) Compositions d'encres
WO2010013815A1 (fr) Composition destinée à inhiber l'expression d'un gène cible
WO2009134027A3 (fr) Anticorps anti-acide nucléique induisant la mort cellulaire de cellules cancéreuses et composition pour prévenir ou traiter des cancers comprenant celui-ci
WO2011046983A3 (fr) Procédés et compositions de modulation de l'expression génique en utilisant des médicaments à base d'oligonucléotides administrés in vivo ou in vitro

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880102931.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08784132

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08784132

Country of ref document: EP

Kind code of ref document: A1